This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: Bioinvent International Ab. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Petra Holmkvist: Innovator in Antibody Research
Introduction
Petra Holmkvist is a prominent inventor based in Kävlinge, Sweden. She has made significant contributions to the field of antibody research, holding three patents that focus on innovative therapeutic approaches.
Latest Patents
Holmkvist's latest patents include the development of antagonistic anti-TNFR2 antibodies. These novel antibody molecules specifically bind to TNFR2 on target cells, effectively blocking TNF-α binding and TNFR2 signaling. This innovation has potential applications in treating cancer and infections caused by intracellular pathogens. Another notable patent describes anti-CTLA-4 antibody molecules and nucleotide sequences that enhance the depletion of CTLA-4 positive cells, such as Tregs. These advancements offer improved treatment options for solid tumors compared to existing therapies like ipilimumab.
Career Highlights
Holmkvist is associated with Bioinvent International AB, where she continues to advance her research in antibody development. Her work is characterized by a commitment to improving therapeutic outcomes for patients with challenging medical conditions.
Collaborations
Holmkvist collaborates with esteemed colleagues, including Ingrid Teige and Monika Semmrich, who contribute to her research endeavors.
Conclusion
Petra Holmkvist's innovative work in antibody research exemplifies her dedication to advancing medical science. Her patents reflect a commitment to developing effective treatments for cancer and other diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile